UBIP (United Biomedical)

UBIP was Founded in 2014 as a spinoff from United Biomedical Inc. and headquartered in Hsinchu, Taiwan, UBI Pharma Inc. is a Taiwan Stock Exchange-listed pharmaceutical company operating PIC/S GMP, US FDA, and Japan PMDA-approved facilities specializing in long-acting protein drugs and specialty sterile injectables (both liquid and lyophilized formulations) with proprietary patented single-chain Fc fusion protein technology and patented long-acting protein drug development platforms, offering comprehensive CDMO services from formulation development through regulatory approval for both protein and small molecule drugs alongside a growing portfolio of approved generic products including Desmopressin Acetate Injection and Voriconazole Injection in the US market, distinguished by its GlaxoSmithKline heritage, over 200 highly skilled professionals, trusted vaccine manufacturing partnerships with Taiwan CDC (Japanese encephalitis and tetanus vaccines), and an impeccable 20+ year track record without a single product recall.